Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Jessica P, Postow, Michael A, Faleck, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982418/
https://www.ncbi.nlm.nih.gov/pubmed/35380715
http://dx.doi.org/10.1093/oncolo/oyac019
_version_ 1784681807468298240
author Harris, Jessica P
Postow, Michael A
Faleck, David M
author_facet Harris, Jessica P
Postow, Michael A
Faleck, David M
author_sort Harris, Jessica P
collection PubMed
description Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.
format Online
Article
Text
id pubmed-8982418
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89824182022-04-05 Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series Harris, Jessica P Postow, Michael A Faleck, David M Oncologist Brief Communications Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases. Oxford University Press 2022-03-02 /pmc/articles/PMC8982418/ /pubmed/35380715 http://dx.doi.org/10.1093/oncolo/oyac019 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Communications
Harris, Jessica P
Postow, Michael A
Faleck, David M
Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title_full Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title_fullStr Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title_full_unstemmed Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title_short Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
title_sort efficacy of infliximab dose escalation in patients with refractory immunotherapy-related colitis: a case series
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982418/
https://www.ncbi.nlm.nih.gov/pubmed/35380715
http://dx.doi.org/10.1093/oncolo/oyac019
work_keys_str_mv AT harrisjessicap efficacyofinfliximabdoseescalationinpatientswithrefractoryimmunotherapyrelatedcolitisacaseseries
AT postowmichaela efficacyofinfliximabdoseescalationinpatientswithrefractoryimmunotherapyrelatedcolitisacaseseries
AT faleckdavidm efficacyofinfliximabdoseescalationinpatientswithrefractoryimmunotherapyrelatedcolitisacaseseries

Ejemplares similares